---
figid: PMC6162436__cancers-10-00329-g003
figlink: /pmc/articles/PMC6162436/figure/cancers-10-00329-f003/
number: F3
caption: Repurposing of drugs on YAP (Yes-1 associated protein)-TEAD (transcriptional
  enhanced associate domain) system through cross-talking pathways. Hippo pathway
  core kinases (in blue) and final effector YAP are modulated by approved drugs through
  different cross-talking pathways. Dobutamine binds β1-adrenergic receptor and promotes
  LATS (large tumor suppressor) 1/2 phosphorylation through PKA (protein kinase A)
  signaling, while melatonin is believed to modulate YAP through pleiotropic mechanisms
  (GPCRs (G-protein coupled receptors) signaling in red). Statins, as HMG-CoA (3-hydroxy-3-methylglutaryl
  CoA) reductase inhibitors, impair Rho signaling in orange and modulate actin cytoskeleton,
  impairing LATS1/2 activation altogether. Tyrosine kinase inhibitors target growth
  factors signaling in cerulean (PI3K-AKT pathway), green (MAPK (mitogen-activated
  protein kinase) pathway) and black and purple (MAPK pathway final effectors) according
  to the proper interested drug. Receptor autophosphorylation inhibitors, such as
  Gefitinib, Erlotinib, and Pazopanib, hit an ATP-binding site. Instead, Dasatinib
  is a Src/Bcr-abl dual inhibitor, while Losmapimod and Trametinib target downstream
  components of MAPK pathway. Dimethylfumarate inhibits GSK3β phosphorylation, preventing
  APC β-catenin destruction complex formation and undermining oncogenic β-catenin
  pathway in the process. Metformin, through AMPK phosphorylation and consequent half-time
  AMOT (Angiomotin) prolongment, promotes phosphorylation-independent YAP cytoplasmic
  sequestration by AMOT in yellow. Digitoxin, Verteporfin and Flufenamic acid and
  derivatives modulate YAP/TEAD interaction, as better discussed in paragraphs 3 and
  4.
pmcid: PMC6162436
papertitle: Repurposing of Drugs Targeting YAP-TEAD Functions.
reftext: Gian Marco Elisi, et al. Cancers (Basel). 2018 Sep;10(9):329.
pmc_ranked_result_index: '15368'
pathway_score: 0.9623945
filename: cancers-10-00329-g003.jpg
figtitle: Repurposing of drugs on YAP (Yes-1 associated protein)-TEAD (transcriptional
  enhanced associate domain) system through cross-talking pathways
year: '2018'
organisms:
- Homo sapiens
ndex: f7b73612-ded9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6162436__cancers-10-00329-g003.html
  '@type': Dataset
  description: Repurposing of drugs on YAP (Yes-1 associated protein)-TEAD (transcriptional
    enhanced associate domain) system through cross-talking pathways. Hippo pathway
    core kinases (in blue) and final effector YAP are modulated by approved drugs
    through different cross-talking pathways. Dobutamine binds β1-adrenergic receptor
    and promotes LATS (large tumor suppressor) 1/2 phosphorylation through PKA (protein
    kinase A) signaling, while melatonin is believed to modulate YAP through pleiotropic
    mechanisms (GPCRs (G-protein coupled receptors) signaling in red). Statins, as
    HMG-CoA (3-hydroxy-3-methylglutaryl CoA) reductase inhibitors, impair Rho signaling
    in orange and modulate actin cytoskeleton, impairing LATS1/2 activation altogether.
    Tyrosine kinase inhibitors target growth factors signaling in cerulean (PI3K-AKT
    pathway), green (MAPK (mitogen-activated protein kinase) pathway) and black and
    purple (MAPK pathway final effectors) according to the proper interested drug.
    Receptor autophosphorylation inhibitors, such as Gefitinib, Erlotinib, and Pazopanib,
    hit an ATP-binding site. Instead, Dasatinib is a Src/Bcr-abl dual inhibitor, while
    Losmapimod and Trametinib target downstream components of MAPK pathway. Dimethylfumarate
    inhibits GSK3β phosphorylation, preventing APC β-catenin destruction complex formation
    and undermining oncogenic β-catenin pathway in the process. Metformin, through
    AMPK phosphorylation and consequent half-time AMOT (Angiomotin) prolongment, promotes
    phosphorylation-independent YAP cytoplasmic sequestration by AMOT in yellow. Digitoxin,
    Verteporfin and Flufenamic acid and derivatives modulate YAP/TEAD interaction,
    as better discussed in paragraphs 3 and 4.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKAG2
  - AJUBA
  - PRKAG3
  - AKT2
  - PRKAB1
  - AMOTL1
  - AKT3
  - RHOD
  - PRKAA1
  - PRKAA2
  - AMOTL2
  - MAPK11
  - MAPK13
  - AKT1
  - MAPK14
  - GSK3B
  - IRS1
  - SOS1
  - GRB2
  - YY1AP1
  - PIK3CD
  - PIK3CG
  - SOS2
  - PIK3CB
  - KRAS
  - NRAS
  - PIK3R3
  - HRAS
  - LATS2
  - PRKAB2
  - CTGF
  - LATS1
  - AXL
  - CTNNB1
  - MAP2K1
  - MAPK1
  - MAPK3
  - PIK3R6
  - PIK3CA
  - MAP2K2
  - MAPK12
  - STK3
  - PIK3R5
  - PIK3R4
  - PRKAG1
  - MST1
  - Dobutamine
  - Gefitinib
  - Melatonin
  - Erlotinib
  - Pazopanib
  - Statins
  - Metformin
  - GDP
  - Dasatinib
  - Dimethylfumarate
  - Digitoxin
  - Verteporfin
  - Losmapimod
  - Trametinib
  - Cancer
  - Noonan syndrome
genes:
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: Ajuba
  symbol: AJUBA
  source: hgnc_symbol
  hgnc_symbol: AJUBA
  entrez: '84962'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMOTL1/2
  symbol: AMOTL1
  source: hgnc_symbol
  hgnc_symbol: AMOTL1
  entrez: '154810'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Rho
  symbol: Rho
  source: hgnc_alias_symbol
  hgnc_symbol: RHOD
  entrez: '29984'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: AMOTL1/2
  symbol: AMOTL2
  source: hgnc_symbol
  hgnc_symbol: AMOTL2
  entrez: '51421'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: IRS-1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: SOs
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: YAP
  symbol: YAP
  source: hgnc_alias_symbol
  hgnc_symbol: YY1AP1
  entrez: '55249'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: SOs
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: LATS1/2
  symbol: LATS2
  source: hgnc_symbol
  hgnc_symbol: LATS2
  entrez: '26524'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: CTGF
  symbol: CTGF
  source: hgnc_symbol
  hgnc_symbol: CTGF
  entrez: '1490'
- word: LATS1/2
  symbol: LATS1
  source: hgnc_symbol
  hgnc_symbol: LATS1
  entrez: '9113'
- word: AXL
  symbol: AXL
  source: hgnc_symbol
  hgnc_symbol: AXL
  entrez: '558'
- word: B-catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MST1/2
  symbol: MST2
  source: hgnc_alias_symbol
  hgnc_symbol: STK3
  entrez: '6788'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: MST1/2
  symbol: MST1
  source: hgnc_symbol
  hgnc_symbol: MST1
  entrez: '4485'
chemicals:
- word: Dobutamine
  source: MESH
  identifier: D004280
- word: Gefitinib
  source: MESH
  identifier: C419708
- word: Melatonin
  source: MESH
  identifier: D008550
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Statins
  source: MESH
  identifier: D019821
- word: Metformin
  source: MESH
  identifier: D008687
- word: GDP
  source: MESH
  identifier: D006153
- word: Dasatinib
  source: MESH
  identifier: C488369
- word: Dimethylfumarate
  source: MESH
  identifier: C056020
- word: Digitoxin
  source: MESH
  identifier: D004074
- word: Verteporfin
  source: MESH
  identifier: C098350
- word: Losmapimod
  source: MESH
  identifier: C543534
- word: Trametinib
  source: MESH
  identifier: C560077
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6162436__F3
redirect_from: /figures/PMC6162436__F3
figtype: Figure
---
